How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

17,247 results for

Anxiety Non-pharmacologic Management

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

121. British guideline on the management of asthma

Doughty Street London WC1N 2PL www.brit-thoracic.org.uk SIGN and BTS consent to the photocopying of this guideline for the purpose of implementation in the NHS in England, Wales, Northern Ireland and Scotland.Contents 1 Introduction 1 1.1 The need for a guideline 1 1.2 Remit of the guideline 1 1.3 Statement of intent 4 2 Key recommendations 6 2.1 Diagnosis 6 2.2 Monitoring 7 2.3 Supported self management 7 2.4 Non-pharmacological management 7 2.5 Pharmacological management 7 2.6 Inhaler devices 8 2.7 (...) Predicting future risk of asthma attacks 32 4.4 Physiological measures 36 4.5 Other approaches 37 5 Supported self management 38 5.1 Effectiveness of supported self management 38 5.2 Components of a self-management programme 38 5.3 Self management in specific patient groups 42 5.4 Adherence and concordance 45 5.5 Implementation in practice 48 6 Non-pharmacological management 50 6.1 Primary prevention 50 6.2 Secondary prevention 557 Pharmacological management 62 7.1 Intermittent reliever therapy 63 7.2

2019 SIGN

122. Managing opioid use disorder in primary care: PEER simplified guideline

, informed decision making with patients. ? Managing patients with OUD in primary care and offering long-term opioid agonist therapy can improve patient outcomes. Adding psychosocial interventions and avoiding punitive measures might also be helpful. All discussions of treatment should involve the patient’s preferences and values. ? Future randomized controlled trials should clarify the effects of pharmacologic treatments on morbidity, mortality, and social functioning (eg, employment); the management (...) , as well as pharmacologic and psychotherapy treatments and various prescribing practices (eg, urine drug testing and contracts). Specific recommendations could not be made for management of comorbidities in patients with OUD owing to limited evidence. Conclusion The recommendations will help simplify the complex management of patients with OUD in primary care. They will aid clinicians and patients in making informed decisions regarding their care. I n 2017, almost 4000 opioid-related deaths occurred

2019 CPG Infobase

123. Guidelines for diagnosing and managing pediatric concussion

and manage significant, prolonged complaints based on specific symptoms, etiology and the time since injury. B 5.9 Assess and treat any physical, cognitive and neurological deficits. B 5.4a(i) Place every child/adolescent on a program of sleep hygiene. C 5.4a(ii) Screen for factors that may influence the child/adolescent’s sleep/wake cycle. B 5.4a(iii) Consider non-pharmacological treatments to improve sleep. C 5.4a(iv) Consider prescribing medication on a short-term basis if sleep has not improved. C (...) medications (especially stimulants); • Mood or anxiety disorders; • Early morning headaches (possible sleep apnea); • Unhealthy habits (lack of exercise, variable sleep-wake schedule, excessive napping, excessive time spent in bed, exercising close to bedtime). Why: To identify factors that could be treated or changed to improve the child/adolescent’s sleep and recovery. Level of evidence: B. 5.4a(iii): Consider non-pharmacological treatments to improve sleep. When: On re-evaluation. Who: Health care

2019 CPG Infobase

124. LSD Treatment in Persons Suffering From Anxiety Symptoms in Severe Somatic Diseases or in Psychiatric Anxiety Disorders

LSD Treatment in Persons Suffering From Anxiety Symptoms in Severe Somatic Diseases or in Psychiatric Anxiety Disorders LSD Treatment in Persons Suffering From Anxiety Symptoms in Severe Somatic Diseases or in Psychiatric Anxiety Disorders - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum (...) illness) is frequent and often insufficiently managed with available medications. This study will evaluate the potential benefits of single treatments with LSD in anxiety disorder. Condition or disease Intervention/treatment Phase Patients Anxiety Disorders Drug: LSD Drug: Placebo Phase 2 Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Estimated Enrollment : 40 participants Allocation: Randomized Intervention Model: Crossover Assignment Intervention

2017 Clinical Trials

125. Glaucoma: diagnosis and management

a copy to their GP and, with patient consent, copy the relevant information to the primary eye care professional nominated by the patient. Advise people to take their discharge summary with them when attending future sight tests. [2017] [2017] 1.5 Treatment 1.5.1 T ake into account any cognitive and physical impairments when making decisions about management and treatment. [2017] [2017] 1.5.2 Check that there are no relevant comorbidities or potential drug interactions before offering pharmacological (...) intervals. [2017] [2017] 1.5.5 Offer another pharmacological treatment to people with an IOP of 24 mmHg or more who cannot tolerate their current treatment. The first choice should be an alternative generic PGA, if available, and if this is not tolerated, offer a beta-blocker. If none of these options are tolerated, offer non-generic PGA, carbonic anhydrase inhibitors, sympathomimetics, miotics or a combination of treatments. [2017] [2017] 1.5.6 Offer a drug from another therapeutic class (beta-blocker

2017 National Institute for Health and Clinical Excellence - Clinical Guidelines

126. Cystic fibrosis: diagnosis and management

on Individual Funding Requests. Be aware that the evidence shows high-frequency chest wall oscillation is not as effective as other airway clearance techniques. 1.6.16 Consider using non-invasive ventilation in people with cystic fibrosis who have moderate or severe lung disease and cannot clear their lungs using standard Cystic fibrosis: diagnosis and management (NG78) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 18 (...) the test for confirmation. 1.6.49 If repeat testing confirms persistent non-tuberculous mycobacteria, do a chest CT scan to look for changes consistent with non-tuberculous mycobacteria disease. 1.6.50 Consider non-tuberculous mycobacterial therapy aimed at eradication for people with cystic fibrosis: Cystic fibrosis: diagnosis and management (NG78) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 24 of 43whose airway

2017 National Institute for Health and Clinical Excellence - Clinical Guidelines

127. Cataracts in adults: management

emergency situations and who to contact eye drops pain management their next appointment and who they will see. After catar After cataract surgery act surgery 1.1.6 At the first appointment after cataract surgery, give people information about: eye drops what to do if their vision changes who to contact if they have concerns or queries when it is appropriate to get new spectacles and how to do so second-eye cataract surgery if there is a cataract in the non-operated eye arrangements for managing ocular (...) . Endophthalmitis Endophthalmitis 1.8.4 Use preoperative antiseptics in line with standard surgical practice. 1.8.5 Use intracameral cefuroxime during cataract surgery to prevent endophthalmitis. 1.8.6 Use commercially prepared or pharmacy-prepared intracameral antibiotic solutions to prevent dilution errors. Cystoid macular oedema Cystoid macular oedema 1.8.7 Consider topical steroids in combination with non-steroidal anti-inflammatory Cataracts in adults: management (NG77) © NICE 2019. All rights reserved

2017 National Institute for Health and Clinical Excellence - Clinical Guidelines

128. Cerebral palsy in under 25s: assessment and management

who are non-ambulant or have low bone mineral density. 1.12.3 Inform children and young people with cerebral palsy and their parents or carers if they are at an increased risk of low-impact fractures. Management Management 1.12.4 If a child and young person with cerebral palsy has 1 or more risk factors for low bone mineral density (see recommendation 1.12.1): assess their dietary intake of calcium and vitamin D and and consider the following laboratory investigations of calcium and vitamin D (...) 25 of 46For children and young people with communication difficulties: Paediatric Pain Profile Non-communicating Children's Pain Checklist – postoperative version For children and young people without communication difficulties: Numeric pain rating scale. 1.13.8 Refer the child or young person for a specialist multidisciplinary team assessment of pain, discomfort, distress and sleep if the cause of these is not clear after routine assessment. Management Management 1.13.9 For reversible causes

2017 National Institute for Health and Clinical Excellence - Clinical Guidelines

129. Non-Invasive Prenatal Testing (NIPT) for common Trisomies (21, 18 and 13)

), and a 26.0% reduction in the number of common fetal trisomy cases undetected (5.2% compared to 7.0%) . The application stated that these findings indicate that NIPT has superior clinical utility to CFTS or 2TMSS in screening for common trisomies. Therapeutic effectiveness (health benefit from change in management) On the basis of the evidence profile, the application suggested that, compared to CFTS or 2TMSS, NIPT for the screening of common fetal trisomies has non-inferior safety and superior (...) Non-Invasive Prenatal Testing (NIPT) for common Trisomies (21, 18 and 13) 1 Public Summary Document Application No. 1492 – Non-Invasive Prenatal Testing Applicant: Royal College of Pathologists of Australasia (RCPA) and Roche Diagnostics Australia Pty Ltd Date of MSAC consideration: MSAC 73 rd Meeting, 26-27 July 2018 Context for decision: MSAC makes its advice in accordance with its Terms of Reference, visit the MSAC website 1. Purpose of application An application requesting Medicare Benefit

2019 Medical Services Advisory Committee

130. More ubiquitous effects from non-pharmacologic than from pharmacologic treatments for fibromyalgia syndrome: A meta-analysis examining six core symptoms. (PubMed)

for the management of multiple core FM symptom domains. Only amitriptyline demonstrated a significant effect on as many as three core FM symptoms, but it exhibited many adverse effects and was subject to early tachyphylaxis. Studies involving non-pharmacologic approaches (n = 64) were typically of poorer quality but were more often dedicated to multidimensional targets. Pool therapy demonstrated significant effects on five symptom domains, repetitive transcranial magnetic stimulation on four domains (...) More ubiquitous effects from non-pharmacologic than from pharmacologic treatments for fibromyalgia syndrome: A meta-analysis examining six core symptoms. This study aimed to characterize and compare the efficacy profile on six fibromyalgia syndrome (FM) core symptoms associated with pharmacologic and non-pharmacologic treatments. We screened PubMed, Embase and the Cochrane Library for FM articles from 1990 to September 2012 to analyse randomized controlled trials comparing pharmacologic or non

Full Text available with Trip Pro

2014 European Journal of Pain

131. Preventing and Managing Infectious Diseases Among People who Inject Drugs in Ontario

Preventing and Managing Infectious Diseases Among People who Inject Drugs in Ontario Evidence Brief Preventing and Managing Infectious Diseases Among People who Inject Drugs in Ontario 28 February 2019 McMaster Health Forum 1 Evidence >> Insight >> Action Evidence Brief: Preventing and Managing Infectious Diseases Among People who Inject Drugs in Ontario 28 February 2019 McMaster Health Forum 2 Evidence >> Insight >> Action McMaster Health Forum The McMaster Health Forum’s goal is to generate (...) . Evidence brief: Preventing and managing infectious diseases among people who inject drugs in Ontario. Hamilton, Ontario: McMaster Health Forum, 28 February 2019. Product registration numbers ISSN 1925-2250 (online) McMaster Health Forum 3 Evidence >> Insight >> Action Table of Contents KEY MESSAGES 5 REPORT 7 THE PROBLEM 8 Injection drug use is associated with increased risk of a range of infectious diseases 9 Stigma and discrimination experienced by people who inject drugs may reduce timely access

2019 McMaster Health Forum

132. Guidelines on Supraventricular Tachycardia (for the management of patients with)

by agreement of the expert panel after thorough deliberation. The document was peer-reviewed by official external reviewers. The strengths of the recommendations and levels of evidence of particular management options were weighed and graded according to predefined scales, as outlined above in Tables and , respectively. Overall, these Guidelines include evidence and expert opinions from several countries. The pharmacological and non-pharmacological antiarrhythmic approaches discussed may therefore include (...) Guidelines on Supraventricular Tachycardia (for the management of patients with) 2019 ESC Guidelines for the management of patients with supraventricular tachycardiaThe Task Force for the management of patients with supraventricular tachycardia of the European Society of Cardiology (ESC) | European Heart Journal | Oxford Academic ') We use cookies to enhance your experience on our website.By continuing to use our website, you are agreeing to our use of cookies. You can change your cookie

Full Text available with Trip Pro

2019 European Society of Cardiology

133. Associations of anxiety with discomfort and tolerance in Chinese patients undergoing esophagogastroduodenoscopy. (PubMed)

Associations of anxiety with discomfort and tolerance in Chinese patients undergoing esophagogastroduodenoscopy. To evaluate the associations of pre-endoscopy anxiety with discomfort and tolerance in patients undergoing unsedated esophagogastroduodenoscopy (EGD).This is a hospital-based cohort study of 348 patients undergoing routine, non-advanced EGD without sedation. The primary outcomes were discomfort and tolerance. The anxiety before endoscopy was evaluated with a 10-point visual analogue (...) -endoscopy anxiety was an independent predictor of severe discomfort and poor tolerance in Chinese patients undergoing unsedated EGD. Our findings suggested the importance of the management of anxiety to reduce adverse endoscopic experience and taking high level of anxiety as an indication for sedation.

Full Text available with Trip Pro

2019 PLoS ONE

134. Social anxiety disorder: recognition, assessment and treatment

6 of 45recover before reaching adulthood. However, if the disorder has persisted into adulthood, the chance of recovery in the absence of treatment is modest when compared with many other common mental health problems. Effective psychological and pharmacological interventions for social anxiety disorder exist but may not be accessed due to poor recognition, inadequate assessment and limited awareness or availability of treatments. Social anxiety disorder is under-recognised in primary care. When (...) follow relevant professional guidance, taking full responsibility for the decision. The service user (or those with authority to give consent on their behalf) should provide informed consent, which should be documented. See Good practice in prescribing and managing medicines and devices for further information. Where recommendations have been made for the use of drugs outside their licensed indications ('off-label use'), these drugs are marked with a footnote in the recommendations. Social anxiety

2013 National Institute for Health and Clinical Excellence - Clinical Guidelines

135. Pharmacological evaluation of novel 5-HT3 receptor antagonist, QCM-13 (N-cyclohexyl-3-methoxyquinoxalin-2-carboxamide) as anti-anxiety agent in behavioral test battery (PubMed)

.) were performed to assess the pharmacological mechanism of the drug.QCM-13 expressed potential anxiolytic effect with significant (P < 0.05) increase in behavioral parameters measured in aforementioned preliminary models. Besides, QCM-13 was unable to reverse the anxiogenic effect of mCPP, but potentiated anxiolytic affect of BUS.The results suggest that QCM-13 can be a potential therapeutic candidate for the management of anxiety-like disorders and combination doses of novel 5-HT3 receptor (...) Pharmacological evaluation of novel 5-HT3 receptor antagonist, QCM-13 (N-cyclohexyl-3-methoxyquinoxalin-2-carboxamide) as anti-anxiety agent in behavioral test battery In the last few decades, serotonin type-3 (5-HT3) receptor antagonists have been identified as potential targets for anxiety disorders. In preclinical studies, 5-HT3 antagonists have shown promising antianxiety effects. In this study, a novel 5-HT3 receptor antagonist, QCM-13(N-cyclohexyl-3-methoxyquinoxalin-2-carboxamide

Full Text available with Trip Pro

2015 Journal of pharmacy & bioallied sciences

136. Prevalence, impact and treatment of generalised anxiety disorder in bipolar disorder: a systematic review and meta-analysis

Prevalence, impact and treatment of generalised anxiety disorder in bipolar disorder: a systematic review and meta-analysis Prevalence, impact and treatment of generalised anxiety disorder in bipolar disorder: a systematic review and meta-analysis | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log (...) in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Prevalence, impact and treatment of generalised anxiety disorder in bipolar disorder: a systematic review and meta-analysis Article Text

2016 Evidence-Based Mental Health

137. Non-ST-elevation myocardial infarction

myocardial injury or infarction as demonstrated by elevation in troponin. There are differences in typical presentation between the sexes. Male patients typically present with chest pressure/discomfort lasting at least several minutes, at times accompanied by sweating, dyspnoea, nausea, and/or anxiety. Women present more commonly with middle/upper back pain or dyspnoea and similar associated symptoms. Symptoms are indistinguishable from those of unstable angina. However, non-ST-elevation myocardial (...) is present, then the patient should be evaluated as an ST-elevation myocardial infarction. NSTEMI, therefore, encompasses a broad spectrum of ischaemic injury to the myocardium, which is detected by elevation of troponin. Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014 Dec

2018 BMJ Best Practice

138. Non-ST-elevation myocardial infarction

myocardial injury or infarction as demonstrated by elevation in troponin. There are differences in typical presentation between the sexes. Male patients typically present with chest pressure/discomfort lasting at least several minutes, at times accompanied by sweating, dyspnoea, nausea, and/or anxiety. Women present more commonly with middle/upper back pain or dyspnoea and similar associated symptoms. Symptoms are indistinguishable from those of unstable angina. However, non-ST-elevation myocardial (...) is present, then the patient should be evaluated as an ST-elevation myocardial infarction. NSTEMI, therefore, encompasses a broad spectrum of ischaemic injury to the myocardium, which is detected by elevation of troponin. Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014 Dec

2018 BMJ Best Practice

139. Management of stable angina

anginaContents 1 Introduction 1 1.1 The need for a guideline 1 1.2 Remit of the guideline 1 1.3 Statement of intent 4 2 Key recommendations 6 2.1 Diagnosis and assessment 6 2.2 Stable angina and non-cardiac surgery 6 3 Diagnosis and assessment 7 3.1 Clinical history and assessment 7 3.2 Diagnostic and prognostic tools 9 3.3 Models of care 12 4 Pharmacological management 13 4.1 Drug monotherapy to alleviate angina symptoms 13 4.2 Combination therapy to alleviate angina symptoms 16 4.3 Drug interventions (...) to prevent new vascular events 17 4.4 Medication concordance 18 5 Interventional cardiology and cardiac surgery 19 5.1 Coronary artery anatomy and definitions 19 5.2 Percutaneous coronary intervention 19 5.3 Coronary artery bypass grafting 21 5.4 Choice of revascularisation technique 23 5.5 Postintervention drug therapy 26 5.6 Postintervention rehabilitation 28 5.7 Managing restenosis 28 5.8 Managing refractory angina 28 6 Stable angina and non-cardiac surgery 30 6.1 Assessment prior to surgery 30 6.2

2018 SIGN

140. Massage, reflexology and other manual methods for pain management in labour. (PubMed)

for Complementary and Integrative Health (4 August 2017), the WHO International Clinical Trials Registry Platform (ICTRP) (4 August 2017) and reference lists of retrieved trials.We included randomised controlled trials comparing manual methods with standard care, other non-pharmacological forms of pain management in labour, no treatment or placebo. We searched for trials of the following modalities: massage, warm packs, thermal manual methods, reflexology, chiropractic, osteopathy, musculo-skeletal manipulation (...) Massage, reflexology and other manual methods for pain management in labour. Many women would like to avoid pharmacological or invasive methods of pain management in labour, and this may contribute towards the popularity of complementary methods of pain management. This review examined the evidence currently available on manual methods, including massage and reflexology, for pain management in labour. This review is an update of the review first published in 2012.To assess the effect, safety

2018 Cochrane

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>